19 completed, 3 terminated, 1 unknown. 14 Phase 2, 7 Phase 1, 2 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 13, Terminated 1 |
| Phase 1 | 7 | Completed 5, Terminated 1, Unknown 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow tyrosinase peptide: new trials by email Literature Review of tyrosinase peptide trials Research Report on tyrosinase peptide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma tyrosinase peptide, gp100 antigen, MART-1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2004-06-01 | 2015-04-15 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | University of Southern California | 42 | 2004-05-01 | 2014-05-22 |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | University of Southern California | 6 | 2003-10-01 | 2014-05-21 |
| Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | University of Southern California | 60 | 2002-02-01 | 2014-05-22 |
| Vaccine Therapy in Treating Patients With Melanoma of the Eye MART-1 antigen, NA17-A antigen, gp100 antigen - Intraocular Melanoma | Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 13 | 2002-02-01 | 2012-09-24 |
| Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Intraocular Melanoma, Melanoma (Skin) | Phase 1 | Completed | University of Southern California | 19 | 2001-10-01 | 2014-05-22 |
| Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma MAGE-10.A2, MART-1 antigen, NY-ESO-1 peptide vaccine - Melanoma (Skin) | Phase 1 | Unknown | Herbert Irving Comprehensive Cancer Center | 2001-10-01 | 2013-12-18 | |
| Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma tyrosinase peptide, MART-1:27-35 peptide vaccine, gp100 antigen - Recurrent Melanoma, Stage IV Melanoma | Not applicable | Completed | National Cancer Institute (NCI) | 30 | 2000-10-01 | 2013-01-25 |
| Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Melanoma (Skin) | Phase 2 | Completed | Eastern Cooperative Oncology Group | 2000-09-01 | 2011-11-08 | |
| Vaccine Therapy in Treating Patients With Melanoma aldesleukin, gp100 antigen, incomplete Freund's adjuvant - Melanoma (Skin) | Phase 2 | Completed | National Cancer Institute (NCI) | 2000-09-01 | 2013-06-19 | |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant - Intraocular Melanoma, Melanoma (Skin) | Phase 1 | Terminated | University of Southern California | 15 | 2000-06-01 | 2014-05-22 |
| Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery Laboratory Biomarker Analysis, Placebo, Sargramostim - Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma | Phase 3 | Completed | National Cancer Institute (NCI) | 815 | 2000-02-23 | 2026-06-24 |
| Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma MART-1 antigen, aldesleukin, gp100 antigen - Melanoma (Skin) | Phase 2 | Terminated | University of Southern California | 25 | 1999-06-01 | 2014-05-22 |
| Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma OVA BiP peptide, gp209-2M antigen, recombinant 70-kD heat-shock protein - Melanoma (Skin) | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 1999-06-01 | 2013-06-19 | |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma MART-1 antigen, filgrastim, flu matrix peptide p58-66 - Melanoma (Skin) | Phase 1 | Completed | Baylor Health Care System | 1999-04-01 | 2013-06-26 | |
| Vaccine Therapy in Treating Patients With Stage IV Melanoma dendritic cell-MART-1 peptide vaccine, gp100 antigen, therapeutic tumor infiltrating lymphocytes - Melanoma (Skin) | Phase 1 | Completed | National Cancer Institute (NCI) | 40 | 1999-04-01 | 2013-02-28 |
| Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12 - Intraocular Melanoma, Melanoma (Skin) | Phase 2 | Completed | University of Southern California | 48 | 1998-11-01 | 2014-05-22 |
| Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma QS21, gp100 antigen, incomplete Freund's adjuvant - Melanoma (Skin) | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 1998-05-01 | 2013-06-25 | |
| Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma aldesleukin, gp100 antigen, incomplete Freund's adjuvant - Melanoma (Skin) | Phase 2 | Completed | University of Virginia | 40 | 1998-04-01 | 2014-12-19 |
| Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery gp100 antigen, incomplete Freund's adjuvant, sargramostim - Melanoma (Skin) | Phase 2 | Completed | University of Southern California | 48 | 1998-03-01 | 2014-05-22 |
Showing 20 of 23. Sign in to see all of them.
Melanoma (22) · Uveal Melanoma (9) · Carcinoma, Renal Cell (1) · Neoplasms (1) · Skin Neoplasms (1) · Urologic Neoplasms (1)
University of Southern California (8) · National Cancer Institute (NCI) (7) · Memorial Sloan Kettering Cancer Center (2) · Baylor Health Care System (1) · Duke University (1) · Eastern Cooperative Oncology Group (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Herbert Irving Comprehensive Cancer Center (1) · University of Virginia (1)
United States (22) · Belgium (1) · Denmark (1)
Jeffrey S. Weber, MD, PhD (7) · Jeffrey Weber (2) · Steven A. Rosenberg, MD, PhD (2) · Brian J. Czerniecki, MD, PhD (1) · Craig L. Slingluff, MD (1) · David H Lawson (1) · Hilliard F. Seigler, MD (1) · Jan U. Prause, MD (1) · John M. Kirkwood, MD (1) · Joseph W. Fay, MD (1) · Kyriakos P. Papadopoulos, MD (1) · Patrick Hwu (1) · Paul B. Chapman, MD (1) · Philip O. Livingston, MD (1) · Svetomir Markovic (1)
PMID 12684398, PMID 14581425, PMID 16237114, PMID 19228745, PMID 22021080, PMID 26351350
U10CA021115 (1)